Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
Reads0
Chats0
TLDR
The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.Abstract:
PURPOSEThe CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies.PATIENTS AND METHODSThis was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8. Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 intravenously weekly for four doses.RESULTSFrom 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13.0 months. Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden. The majority of adverse events occurred during the first infusion and were grade 1 or 2; fe...read more
Citations
More filters
Journal ArticleDOI
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Bertrand Coiffier,Eric Lepage,Josette Brière,Raoul Herbrecht,Hervé Tilly,Reda Bouabdallah,Pierre Morel,Eric Van Den Neste,Gilles Salles,Philippe Gaulard,Felix Reyes,Pierre Lederlin,Christian Gisselbrecht +12 more
TL;DR: A randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma found the rate of complete response was significantly higher in the group that received CHOP plus r ituximabs than in thegroup that receivedCHOP alone.
Journal ArticleDOI
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.
Nancy L. Harris,Elaine S. Jaffe,Jacques Diebold,G. Flandrin,H. Konrad Muller-Hermelink,James W. Vardiman,T. Andrew Lister,Clara D. Bloomfield +7 more
TL;DR: The experience of developing the WHO Classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies.
Journal ArticleDOI
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
Guillaume Cartron,Laurent Dacheux,Gilles Salles,Philippe Solal-Celigny,Pierre Bardos,Philippe Colombat,Hervé Watier +6 more
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
Journal ArticleDOI
Protein therapeutics: a summary and pharmacological classification
TL;DR: Some of the key characteristics of protein therapeutics are overviewed, a new classification of these proteins according to their pharmacological action is suggested and this article summarizes the more than 130 protein therapeuticals used currently and suggests a new classifications.
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff Mitchell E,Kristin Carner,Karen S. Chambers,Paul Chinn,John E Leonard,Ron Raab,Roland A. Newman,Nabil Hanna,Darrell R Anderson +8 more
TL;DR: In vitro studies showed the ability of C2B8 to bind human C1q, mediate complement-dependent cell lysis of human B-lymphoid cell lines, and lyse human target cells through antibody-dependent cellular cytotoxicity and the possibility of using an "immunologically active" chimeric anti-CD20 antibody as an alternative approach in the treatment of B-cell lymphoma.
Journal ArticleDOI
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
David G. Maloney,Antonio J. Grillo-Lopez,Christine A. White,David Bodkin,Russell J. Schilder,James A. Neidhart,Nalini Janakiraman,Kenneth A. Foon,Tina Marie Liles,Brian Dallaire,Ken Wey,Ivor Royston,Thomas A. Davis,Ronald Levy +13 more
TL;DR: Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
Journal ArticleDOI
Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
David G. Maloney,TM Liles,Debra K. Czerwinski,C Waldichuk,J. Rosenberg,Antonio J. Grillo-Lopez,Ronald Levy +6 more
TL;DR: CD20+ B cells were rapidly and specifically depleted in the peripheral blood at 24 to 72 hours and remained depleted for at least 2 to 3 months in most patients, and were used to design a multiple-dose phase I/II study.
Journal ArticleDOI
Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
Kenneth C. Anderson,Michael P. Bates,B Slaughenhoupt,Geraldine S. Pinkus,Stuart F. Schlossman,Lee M. Nadler +5 more
TL;DR: A hypothetical model is derived that relates the malignant B cell to its normal cellular counterpart on the basis of cell surface expression of this panel of B cell-restricted and B cell -associated antigens.